NCT04878315View on ClinicalTrials.gov

Bioequivalence Study Between Capoten Versus Captopril Reference Product in Healthy Adult Participants Under Fasting Conditions

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

February 13, 2022

Primary Completion Date

March 25, 2022

Study Completion Date

March 25, 2022

Conditions
Healthy Volunteers
Interventions
DRUG

Capoten

Capoten will be administered per the treatment sequence

DRUG

Captopril

Captopril will be administered per the treatment sequence

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT04878315 - Bioequivalence Study Between Capoten Versus Captopril Reference Product in Healthy Adult Participants Under Fasting Conditions | Biotech Hunter | Biotech Hunter